JP6461097B2 - Ｌｒｒｋ２阻害剤としてのアリールピロロピリジン誘導化合物 - Google Patents

Ｌｒｒｋ２阻害剤としてのアリールピロロピリジン誘導化合物 Download PDF

Info

Publication number
JP6461097B2
JP6461097B2 JP2016508109A JP2016508109A JP6461097B2 JP 6461097 B2 JP6461097 B2 JP 6461097B2 JP 2016508109 A JP2016508109 A JP 2016508109A JP 2016508109 A JP2016508109 A JP 2016508109A JP 6461097 B2 JP6461097 B2 JP 6461097B2
Authority
JP
Japan
Prior art keywords
pyridine
pyrrolo
carbonitrile
amino
lrrk2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016508109A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016516791A5 (enExample
JP2016516791A (ja
Inventor
ティモシー ベッドフォード，シオモン
ティモシー ベッドフォード，シオモン
チェン，イ−ジェン
ワン，イカン
スチュアート ウィリアムソン，ダグラス
スチュアート ウィリアムソン，ダグラス
Original Assignee
ハー・ルンドベック・アクチエゼルスカベット
バーナリス（アール アンド ディ）リミテッド
バーナリス（アール アンド ディ）リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハー・ルンドベック・アクチエゼルスカベット, バーナリス（アール アンド ディ）リミテッド, バーナリス（アール アンド ディ）リミテッド filed Critical ハー・ルンドベック・アクチエゼルスカベット
Publication of JP2016516791A publication Critical patent/JP2016516791A/ja
Publication of JP2016516791A5 publication Critical patent/JP2016516791A5/ja
Application granted granted Critical
Publication of JP6461097B2 publication Critical patent/JP6461097B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2016508109A 2013-04-18 2014-04-14 Ｌｒｒｋ２阻害剤としてのアリールピロロピリジン誘導化合物 Expired - Fee Related JP6461097B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201300231 2013-04-18
DKPA201300231 2013-04-18
PCT/EP2014/057482 WO2014170248A1 (en) 2013-04-18 2014-04-14 Arylpyrrolopyridine derived compounds as lrrk2 inhibitors

Publications (3)

Publication Number Publication Date
JP2016516791A JP2016516791A (ja) 2016-06-09
JP2016516791A5 JP2016516791A5 (enExample) 2018-08-09
JP6461097B2 true JP6461097B2 (ja) 2019-01-30

Family

ID=59093654

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016508109A Expired - Fee Related JP6461097B2 (ja) 2013-04-18 2014-04-14 Ｌｒｒｋ２阻害剤としてのアリールピロロピリジン誘導化合物

Country Status (8)

Country Link
US (3) US9499542B2 (enExample)
EP (1) EP2986608B1 (enExample)
JP (1) JP6461097B2 (enExample)
CN (1) CN105263930B (enExample)
AR (1) AR095885A1 (enExample)
ES (1) ES2642204T3 (enExample)
TW (1) TW201533043A (enExample)
WO (1) WO2014170248A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017156493A1 (en) 2016-03-11 2017-09-14 Denali Therapeutics Inc. Compounds, compositions, and methods
TW201533043A (zh) 2013-04-18 2015-09-01 Lundbeck & Co As H 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物
US11214565B2 (en) 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
JP2018537502A (ja) 2015-12-16 2018-12-20 サウザーン リサーチ インスチチュート ピロロピリミジン化合物、キナーゼｌｒｒｋ２阻害剤としての使用、及びその調製方法
PT3472153T (pt) * 2016-06-16 2021-12-31 Denali Therapeutics Inc Pirimidin-2-ilamino-1h-pirazóis como inibidores de lrrk2 para uso no tratamento de distúrbios neurodegenerativos
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
JOP20190126A1 (ar) * 2016-12-22 2019-05-28 H Lundbeck As بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1
WO2018155947A1 (ko) 2017-02-24 2018-08-30 재단법인 대구경북첨단의료산업진흥재단 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물
AU2018239798B2 (en) 2017-03-23 2020-08-27 Daegu Gyeongbuk Institute Of Science And Technology Pyrrolo-pyridine derivative compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of protein kinase-related diseases
JOP20180094A1 (ar) 2017-10-18 2019-04-18 Hk Inno N Corp مركب حلقي غير متجانس كمثبط بروتين كيناز
SG11202005264PA (en) * 2017-12-05 2020-07-29 Oscotec Inc Pyrrolo(pyrazolo)pyrimidine derivative as lrrk2 inhibitor
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
RU2020118913A (ru) 2017-12-14 2022-01-14 Х. Лундбекк А/С (H. Lundbeck A/S) Виды комбинированного лечения, предусматривающего введение 1h-пиразолo[4,3-b]пиридинов
US11535611B2 (en) 2017-12-20 2022-12-27 H. Lundbeck A/S Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors
WO2020023393A1 (en) * 2018-07-23 2020-01-30 Bioblocks, Inc. Kinase antagonists and methods for making and using them
KR101990739B1 (ko) * 2018-07-24 2019-06-19 재단법인 대구경북첨단의료산업진흥재단 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물
KR101992059B1 (ko) * 2018-08-23 2019-06-21 재단법인 대구경북첨단의료산업진흥재단 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
CA3168211A1 (en) 2019-01-18 2020-07-23 Voronoi Co., Ltd. Pyrrolopyridine derivative and use thereof for preventing or treating protein kinase related disease
KR102133595B1 (ko) * 2019-05-31 2020-07-13 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
KR20230091150A (ko) * 2020-10-29 2023-06-22 수저우 야바오 파마슈티걸 알앤디 컴퍼니 리미티드 치환된 디아릴아민 화합물 및 이의 약학적 조성물, 제조 방법과 용도
KR20220081631A (ko) 2020-12-09 2022-06-16 보로노이 주식회사 염증성 질환의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도
CN112852954A (zh) * 2021-03-16 2021-05-28 江苏贝格尔生物医药有限公司 一种检测lrrk2基因1628多态性的引物和探针及试剂盒
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus
US20250361230A1 (en) * 2022-06-06 2025-11-27 The USA, as Represented by the Secretary, Dept. of Heath and Human Services LATS Inhibitors and Uses Thereof
CN119707961B (zh) * 2024-12-02 2025-10-24 重庆飞因科生物科技有限公司 吡啶并吡咯类氨基酸衍生物及其在制备富亮氨酸重复激酶2抑制剂中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004101565A2 (en) 2003-05-16 2004-11-25 Eisai Co., Ltd. Jnk inhibitors
EP1968568A4 (en) 2005-12-22 2011-04-13 Glaxosmithkline Llc HEMMER OF NUTS ACTIVITY
EP1979353A2 (en) * 2006-01-19 2008-10-15 OSI Pharmaceuticals, Inc. Fused heterobicyclic kinase inhibitors
WO2007090141A2 (en) * 2006-02-01 2007-08-09 Smithkline Beecham Corporation Pyrrolo [2, 3, b] pyridine derivatives useful as raf kinase inhibitors
GB0617161D0 (en) 2006-08-31 2006-10-11 Vernalis R&D Ltd Enzyme inhibitors
WO2008110508A1 (en) * 2007-03-09 2008-09-18 Glaxo Group Limited Pyrrolo-pyridine derivatives for the treatment of disorders associated with inappropriate ikk1 activity
NZ579635A (en) 2007-03-20 2011-07-29 Curis Inc Fused amino pyridine as hsp90 inhibitors
KR101700229B1 (ko) * 2009-03-19 2017-01-26 메디칼 리서치 카운실 테크놀로지 화합물들
GB201008134D0 (en) * 2010-05-14 2010-06-30 Medical Res Council Technology Compounds
GB201015949D0 (en) 2010-09-22 2010-11-03 Medical Res Council Technology Compounds
KR101984480B1 (ko) 2011-04-05 2019-05-31 슬로안-케테링인스티튜트퍼캔서리서치 Ｈｓｐ９０ 억제제
TW201533043A (zh) 2013-04-18 2015-09-01 Lundbeck & Co As H 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物

Also Published As

Publication number Publication date
EP2986608A1 (en) 2016-02-24
HK1222387A1 (en) 2017-06-30
JP2016516791A (ja) 2016-06-09
CN105263930B (zh) 2017-06-09
US9675594B2 (en) 2017-06-13
US20160102089A1 (en) 2016-04-14
TW201533043A (zh) 2015-09-01
US20140315901A1 (en) 2014-10-23
ES2642204T3 (es) 2017-11-15
AR095885A1 (es) 2015-11-18
EP2986608B1 (en) 2017-08-23
WO2014170248A1 (en) 2014-10-23
US9499542B2 (en) 2016-11-22
US20170020850A1 (en) 2017-01-26
CN105263930A (zh) 2016-01-20

Similar Documents

Publication Publication Date Title
JP6461097B2 (ja) Ｌｒｒｋ２阻害剤としてのアリールピロロピリジン誘導化合物
US20220305014A1 (en) Inhibitors of cyclin dependent kinase 7 (cdk7)
CN107072985B (zh) 治疗性抑制化合物
US11918592B2 (en) Inhibitors of cyclin dependent kinase 7 (CDK7)
TW201825472A (zh) 新穎化合物類
US11161854B2 (en) Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof
EP2933248A1 (en) Novel renin inhibitor
TW202317544A (zh) 吡啶酮mk2抑制劑及其用途
WO2019074810A1 (en) INDAZOLYL-SPIRO [2,3] HEXANE-CARBONITRILE DERIVATIVES AS INHIBITORS OF LRRK2, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
CA2946475A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
JP7233130B2 (ja) Ｉｒａｋ４阻害剤としての新規な三環式化合物
JP6284949B2 (ja) Ｌｒｒｋ２阻害剤としてのアミノピリジン誘導化合物
US20230227483A1 (en) Pyrimidine compounds for use as map4k1 inhibitors
US20200190035A1 (en) Rock-inhibiting compound and uses thereof
HK1222387B (en) Arylpyrrolopyridine derived compounds as lrrk2 inhibitors
EA048523B1 (ru) Пиримидиновые соединения для применения в качестве ингибиторов map4k1
TW202442651A (zh) 富白胺酸重複激酶2（lrrk2）抑制劑
EA048250B1 (ru) Производные хинолина, как ингибиторы протеинкиназы
HK1241705A1 (zh) 治疗性抑制化合物

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170403

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180403

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20180629

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181127

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181225

R150 Certificate of patent or registration of utility model

Ref document number: 6461097

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees